PT  - JOURNAL ARTICLE
AU  - Rego, Natalia
AU  - Costábile, Alicia
AU  - Paz, Mercedes
AU  - Salazar, Cecilia
AU  - Perbolianachis, Paula
AU  - Spangenberg, Lucía
AU  - Ferrés, Ignacio
AU  - Arce, Rodrigo
AU  - Fajardo, Alvaro
AU  - Arleo, Mailen
AU  - Possi, Tania
AU  - Bellini, Inés
AU  - Bilbao, Lucia
AU  - Reyes, Natalia
AU  - Bentancor, Ma Noel
AU  - Lizasoain, Andrés
AU  - Benítez, María José
AU  - Castells, Matías
AU  - Victoria, Matías
AU  - Maya, Leticia
AU  - Bortagaray, Viviana
AU  - Moller, Ana
AU  - Bello, Gonzalo
AU  - Arantes, Ighor
AU  - Brandes, Mariana
AU  - Smircich, Pablo
AU  - Chappos, Odhille
AU  - Duquía, Melissa
AU  - González, Belén
AU  - Griffero, Luciana
AU  - Méndez, Mauricio
AU  - Techera, Ma Pía
AU  - Zanetti, Juan
AU  - Rivera, Bernardina
AU  - Maidana, Matías
AU  - Alonso, Martina
AU  - Alonso, Cecilia
AU  - Medina, Julio
AU  - Albornoz, Henry
AU  - Colina, Rodney
AU  - Noya, Veronica
AU  - Iraola, Gregorio
AU  - Fernández-Calero, Tamara
AU  - Moratorio, Gonzalo
AU  - Moreno, Pilar
TI  - Implementation of a qPCR assay coupled with genomic surveillance for real-time monitoring of SARS-CoV-2 variants of concern
AID  - 10.1101/2021.05.20.21256969
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.20.21256969
4099  - http://medrxiv.org/content/early/2021/05/22/2021.05.20.21256969.short
4100  - http://medrxiv.org/content/early/2021/05/22/2021.05.20.21256969.full
AB  - We developed a genomic surveillance program for real-time monitoring of SARS-CoV-2 variants of concern in Uruguay. Here, we present the first results, including the proposed qPCR-VOC method, the general workflow and the report of the introduction and community transmission of the VOC P.1 in Uruguay in multiple independent events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by FOCEM-Fondo para la Convergencia Estructural del Mercosur (COF03/11). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Ministry of Health (Uruguay) is the main health Institution in our country. It is a dedicated ethics oversight body and has granted us the ethical approval for this work. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData was uploaded to GISAID